Table 20, Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3c Serotonin–norepinephrine reuptake inhibitors (SNRIs) versus placebo - Service delivery Models and settings for delivery of services

Table 20Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3c Serotonin–norepinephrine reuptake inhibitors (SNRIs) versus placebo

Study	Population	Intervention	Comparison	Comments
Inpatient setting (K=2, N=283)
Guelfi 1995 RCT France	Inpatient N=93 Baseline severity: More severe Mean age (years): 56 Sex (% female): 85 Ethnicity (% BME): NR	Venlafaxine 150-375mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission
Sheehan 2009ba RCT US	Inpatient N=190 Baseline severity: More severe Mean age (years): 40.8 Sex (% female): 56 Ethnicity (% BME): NR	Venlafaxine 225-375mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission
Outpatient setting (K=26, N=6,784)
Brannan 2005 RCT US	Outpatient N=282 Baseline severity: More severe Mean age (years): 40.6 Sex (% female): 65 Ethnicity (% BME): 20	Duloxetine 60mg/day	Placebo 2 capsules/day	Treatment duration (weeks): 7 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Cutler 2009 RCT US	Outpatient N=308 Baseline severity: More severe Mean age (years): 41.3 Sex (% female): 63 Ethnicity (% BME): 28	Duloxetine 60mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Detke 2002a RCT US	Outpatient N=267 Baseline severity: More severe Mean age (years): 41 Sex (% female): 69 Ethnicity (% BME): 22	Duloxetine 60mg/day	Placebo 3 capsules/day	Treatment duration (weeks): 9 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Detke 2002b RCT US	Outpatient N=245 Baseline severity: More severe Mean age (years): 42.4 Sex (% female): 67 Ethnicity (% BME): 14	Duloxetine 40-60mg/day	Placebo 2-3 capsules/day	Treatment duration (weeks): 9 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Detke 2004a RCT US	Outpatient N=281 Baseline severity: More severe Mean age (years): 43.8 Sex (% female): 74 Ethnicity (% BME): 0	Duloxetine 80mg/day or 120mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Eli Lilly HMAT-Aa RCT US	Outpatient N=174 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Duloxetine 80mg/day or 120mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Goldstein 2002a RCT US	Outpatient N=140 Baseline severity: More severe Mean age (years): 41.9 Sex (% female): 66 Ethnicity (% BME): 15	Duloxetine 40-120mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Goldstein 2004a RCT US	Outpatient N=180 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 63 Ethnicity (% BME): 16	Duloxetine 80mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Hewett 2009 RCT Country NR	Outpatient N=384 Baseline severity: More severe Mean age (years): 42.2 Sex (% female): 70 Ethnicity (% BME): 3	Venlafaxine 75-150mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Hewett 2010 RCT Country NR	Outpatient N=385 Baseline severity: More severe Mean age (years): 44.3 Sex (% female): 68 Ethnicity (% BME): 5	Venlafaxine 75-150mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Higuchi 2016 RCT Japan	Outpatient N=538 Baseline severity: More severe Mean age (years): 38.4 Sex (% female): NR Ethnicity (% BME): 100	Venlafaxine 75mg/day or 75-225mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Khan 1998 RCT US	Outpatient N=403 Baseline severity: More severe Mean age (years): 41.7 Sex (% female): 63 Ethnicity (% BME): NR	Venlafaxine 75mg/day, 150mg/day or 200mg/day	Placebo	Treatment duration (weeks): 12 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint
Levin 2013 RCT US	Outpatient N=103 Baseline severity: More severe Mean age (years): 35.1 Sex (% female): 26 Ethnicity (% BME): 54	Venlafaxine maximum 375mg/day	Placebo	Treatment duration (weeks): 12 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Mendels 1993 RCT US	Outpatient N=157 Baseline severity: More severe Mean age (years): 38.5 Sex (% female): 65 Ethnicity (% BME): NR	Venlafaxine 150-200mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Nemeroff 2007a RCT US	Outpatient N=204 Baseline severity: More severe Mean age (years): 40.2 Sex (% female): 59 Ethnicity (% BME): 10	Venlafaxine 75-225mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Nierenberg 2007a RCT US	Outpatient N=410 Baseline severity: More severe Mean age (years): 41.6 Sex (% female): 63 Ethnicity (% BME): 22	Duloxetine 60mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Perahia 2006a RCT Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia	Outpatient N=295 Baseline severity: More severe Mean age (years): 45 Sex (% female): 69 Ethnicity (% BME): 0	Duloxetine 80mg/day or 120mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Raskin 2007 RCT US	Outpatient N=311 Baseline severity: More severe Mean age (years): 72.8 Sex (% female): 59 Ethnicity (% BME): 22	Duloxetine 60mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Robinson 2014 RCT France, Mexico, Puerto Rico, & US	Outpatient N=370 Baseline severity: More severe Mean age (years): 72.9 Sex (% female): 63 Ethnicity (% BME): 22	Duloxetine 60mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Rudolph 1999a RCT US	Outpatient N=192 Baseline severity: More severe Mean age (years): 40 Sex (% female): 71 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Remission
Schweizer 1994a RCT US	Outpatient N=151 Baseline severity: More severe Mean age (years): 41.5 Sex (% female): 69 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Study F1J-MC-HMAQ-Study Group Ba RCT US	Outpatient N=157 Baseline severity: More severe Mean age (years): 40.6 Sex (% female): NR Ethnicity (% BME): NR	Duloxetine 40-120mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission
Thase 1997 RCT US	Outpatient N=197 Baseline severity: More severe Mean age (years): 41 Sex (% female): 61 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Placebo 1-3 capsules/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Remission
VEN 600A-303 (FDA) RCT US	Outpatient N=165 Baseline severity: More severe Mean age (years): 38.5 Sex (% female): 69 Ethnicity (% BME): NR	Venlafaxine 150-225mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
VEN 600A-313 (FDA) RCT US	Outpatient N=237 Baseline severity: More severe Mean age (years): 38.4 Sex (% female): 67 Ethnicity (% BME): NR	Venlafaxine 75mg/day or 200mg/day	Placebo	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
VEN XR 367 (FDA)^a RCT Europe	Outpatient N=248 Baseline severity: More severe Mean age (years): NR Sex (% female): 66 Ethnicity (% BME): NR	Venlafaxine 75mg/day or 150mg/day	Placebo	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score

Study

Population

Intervention

Comparison

Comments

Inpatient setting (K=2, N=283)

Guelfi 1995

RCT

France

Inpatient

N=93

Baseline severity: More severe

Mean age (years): 56

Sex (% female): 85

Ethnicity (% BME): NR

Venlafaxine 150-375mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission

Sheehan 2009ba

RCT

Inpatient

N=190

Baseline severity: More severe

Mean age (years): 40.8

Sex (% female): 56

Ethnicity (% BME): NR

Venlafaxine 225-375mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission

Outpatient setting (K=26, N=6,784)

Brannan 2005

RCT

Outpatient

N=282

Baseline severity: More severe

Mean age (years): 40.6

Sex (% female): 65

Ethnicity (% BME): 20

Duloxetine 60mg/day

Placebo 2 capsules/day

Treatment duration (weeks): 7

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Cutler 2009

RCT

Outpatient

N=308

Baseline severity: More severe

Mean age (years): 41.3

Sex (% female): 63

Ethnicity (% BME): 28

Duloxetine 60mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Detke 2002a

RCT

Outpatient

N=267

Baseline severity: More severe

Mean age (years): 41

Sex (% female): 69

Ethnicity (% BME): 22

Duloxetine 60mg/day

Placebo 3 capsules/day

Treatment duration (weeks): 9

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Detke 2002b

RCT

Outpatient

N=245

Baseline severity: More severe

Mean age (years): 42.4

Sex (% female): 67

Ethnicity (% BME): 14

Duloxetine 40-60mg/day

Placebo 2-3 capsules/day

Treatment duration (weeks): 9

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Detke 2004a

RCT

Outpatient

N=281

Baseline severity: More severe

Mean age (years): 43.8

Sex (% female): 74

Ethnicity (% BME): 0

Duloxetine 80mg/day or 120mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Eli Lilly HMAT-Aa

RCT

Outpatient

N=174

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Duloxetine 80mg/day or 120mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Goldstein 2002a

RCT

Outpatient

N=140

Baseline severity: More severe

Mean age (years): 41.9

Sex (% female): 66

Ethnicity (% BME): 15

Duloxetine 40-120mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Goldstein 2004a

RCT

Outpatient

N=180

Baseline severity: More severe

Mean age (years): 40.5

Sex (% female): 63

Ethnicity (% BME): 16

Duloxetine 80mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Hewett 2009

RCT

Country NR

Outpatient

N=384

Baseline severity: More severe

Mean age (years): 42.2

Sex (% female): 70

Ethnicity (% BME): 3

Venlafaxine 75-150mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Hewett 2010

RCT

Country NR

Outpatient

N=385

Baseline severity: More severe

Mean age (years): 44.3

Sex (% female): 68

Ethnicity (% BME): 5

Venlafaxine 75-150mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Higuchi 2016

RCT

Japan

Outpatient

N=538

Baseline severity: More severe

Mean age (years): 38.4

Sex (% female): NR

Ethnicity (% BME): 100

Venlafaxine 75mg/day or 75-225mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Khan 1998

RCT

Outpatient

N=403

Baseline severity: More severe

Mean age (years): 41.7

Sex (% female): 63

Ethnicity (% BME): NR

Venlafaxine 75mg/day, 150mg/day or 200mg/day

Placebo

Treatment duration (weeks): 12

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint

Levin 2013

RCT

Outpatient

N=103

Baseline severity: More severe

Mean age (years): 35.1

Sex (% female): 26

Ethnicity (% BME): 54

Venlafaxine maximum 375mg/day

Placebo

Treatment duration (weeks): 12

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Mendels 1993

RCT

Outpatient

N=157

Baseline severity: More severe

Mean age (years): 38.5

Sex (% female): 65

Ethnicity (% BME): NR

Venlafaxine 150-200mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Nemeroff 2007a

RCT

Outpatient

N=204

Baseline severity: More severe

Mean age (years): 40.2

Sex (% female): 59

Ethnicity (% BME): 10

Venlafaxine 75-225mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Nierenberg 2007a

RCT

Outpatient

N=410

Baseline severity: More severe

Mean age (years): 41.6

Sex (% female): 63

Ethnicity (% BME): 22

Duloxetine 60mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Perahia 2006a

RCT

Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia

Outpatient

N=295

Baseline severity: More severe

Mean age (years): 45

Sex (% female): 69

Ethnicity (% BME): 0

Duloxetine 80mg/day or 120mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Raskin 2007

RCT

Outpatient

N=311

Baseline severity: More severe

Mean age (years): 72.8

Sex (% female): 59

Ethnicity (% BME): 22

Duloxetine 60mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Robinson 2014

RCT

France, Mexico, Puerto Rico, & US

Outpatient

N=370

Baseline severity: More severe

Mean age (years): 72.9

Sex (% female): 63

Ethnicity (% BME): 22

Duloxetine 60mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Rudolph 1999a

RCT

Outpatient

N=192

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 71

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Remission

Schweizer 1994a

RCT

Outpatient

N=151

Baseline severity: More severe

Mean age (years): 41.5

Sex (% female): 69

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Study F1J-MC-HMAQ-Study Group Ba

RCT

Outpatient

N=157

Baseline severity: More severe

Mean age (years): 40.6

Sex (% female): NR

Ethnicity (% BME): NR

Duloxetine 40-120mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission

Thase 1997

RCT

Outpatient

N=197

Baseline severity: More severe

Mean age (years): 41

Sex (% female): 61

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Placebo 1-3 capsules/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Remission

VEN 600A-303 (FDA)

RCT

Outpatient

N=165

Baseline severity: More severe

Mean age (years): 38.5

Sex (% female): 69

Ethnicity (% BME): NR

Venlafaxine 150-225mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

VEN 600A-313 (FDA)

RCT

Outpatient

N=237

Baseline severity: More severe

Mean age (years): 38.4

Sex (% female): 67

Ethnicity (% BME): NR

Venlafaxine 75mg/day or 200mg/day

Placebo

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

VEN XR 367 (FDA)^a

RCT

Europe

Outpatient

N=248

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 66

Ethnicity (% BME): NR

Venlafaxine 75mg/day or 150mg/day

Placebo

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

a: Three-armed trial but where possible the demographics reported here are for only the two relevant arms.
: BME: black, minority, ethnic; mg: milligrams; N: number of participants; NR: not reported; RCT: randomised controlled trial.

From: Service delivery Models and settings for delivery of services

Cover of Service delivery Models and settings for delivery of services

Service delivery Models and settings for delivery of services: Depression in adults: Evidence review A.

NICE Guideline, No. 222.

London: National Institute for Health and Care Excellence (NICE); 2022 Jun.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.